The 2023 Alzheimer’s Association International Conference (AAIC), which is the largest international conference dedicated to advancing dementia science, is happening this week from July 16 to 20. One of the conference’s highlights includes utilising personalised and precision medicine towards advancing Alzheimer’s disease (AD) treatments.

According to the World Health Organization, over 55 million people worldwide currently suffer from AD, the most common form of dementia. At this year’s AAIC, two new pipeline precision medicine strategies were mentioned; both of which use Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-based technology.

One of them will aim to reduce the gene that is notably associated with AD, the APO-e4 gene. The second one will focus on reducing the production of beta-amyloid, a toxic protein in the brain that is a known hallmark of AD.

Interestingly, CRISPR-based technology is typically used in the field of oncology, but not in AD. In the oncology space, CRISPR is used to splice genetic mutations linked to cancer, such as the BRCA1 and BRCA2 mutations. Likewise, this same precision medicine tool can be used to target and splice specific genes associated with AD.

According to GlobalData, the global AD market is currently valued at $2.7bn and is forecasted to grow at a compound annual growth rate (CAGR) of 29%, reaching about $16bn by 2030. Given the high success rate of precision medicine in the oncology space, the benefits of precision medicine will be significant should they transfer to AD treatments. Technological advancements in precision medicine for AD treatments will surely contribute to the global AD market’s aggressive growth.